指南与共识鼻科

遗传性出血性毛细血管扩张症相关鼻出血患者硬化治疗共识

Consensus on Sclerotherapy for Patients With Hereditary Hemorrhagic Telangiectasia-Related Epistaxis.
指南 / 共识 · JAMA Otolaryngol Head Neck Surg · 2025-01-01

该研究采用改良德尔菲法,由6名来自意大利、西班牙和美国的专家通过3轮问卷和讨论,就遗传性出血性毛细血管扩张症相关鼻出血的硬化治疗达成30条共识声明,涵盖患者选择、操作环境、预防措施和从业者资质等7个领域,旨在促进该疗法的安全应用。

要点

  • 病情稳定的遗传性出血性毛细血管扩张症患者适合接受硬化治疗,需根据病史和合并症个体化预防。
  • 诊室内硬化治疗具有快速可及、患者满意度高和避免全身麻醉风险等优势。
  • 根据2015年欧洲心脏病学会指南,患者准备时推荐抗生素预防,通常无需禁食。

核心结论

  • 6名专家的共识产生了30条指导患者护理和安全实施操作的声明。
  • 这些声明虽非正式治疗指南,但为希望采用或对标专家建议的临床医生提供了有价值的见解。
  • 鼓励进一步验证和研究以确保这些共识声明改善患者护理和结局。

研究设计与样本

  • 本研究为调查性研究,采用改良德尔菲方案在6名专家组成的小组中达成关于硬化治疗的共识。
  • 德尔菲共识通过在线会议和通过Google Forms发送的问卷调查进行。
  • 6名专家来自意大利、西班牙和美国,每人均在遗传性出血性毛细血管扩张症相关鼻出血和皮肤毛细血管扩张的硬化治疗使用方面拥有超过10年经验。
  • 该方法包括3轮评分,其间穿插由经验丰富的协调者主持的面对面讨论以解决分歧。
  • 共识定义为6名小组成员中4人同意。

主要发现

  • 经过讨论和澄清后,进行了3轮调查,最终就7个领域的全部30条声明达成共识。
  • 6名专家的共识表明,病情稳定的遗传性出血性毛细血管扩张症患者适合接受硬化治疗,需根据病史和合并症采取个体化预防措施。
  • 诊室内硬化治疗具有多个优势,包括快速可及、患者满意度高和消除全身麻醉风险,尽管偶有血管迷走神经事件和中度出血发生。
  • 不良事件通常为轻至中度,严重出血罕见。
  • 从业者应具备内镜或鼻镜检查专长、全面的病理学知识以及接受过经验丰富专业人员的培训。

关键数值与推荐

  • 共识定义为6名小组成员中4人同意。
  • 共识就7个领域的全部30条声明达成一致。
  • 根据2015年欧洲心脏病学会指南,患者准备时推荐抗生素预防,通常无需禁食。
  • 已确定预防鼻中隔穿孔和黑矇等并发症的具体预防措施。

临床怎么用

  • 病情稳定的遗传性出血性毛细血管扩张症患者适合接受硬化治疗,需根据病史和合并症采取个体化预防措施。
  • 诊室内硬化治疗具有快速可及、患者满意度高和消除全身麻醉风险等优势。
  • 根据2015年欧洲心脏病学会指南,患者准备时推荐抗生素预防,通常无需禁食。
  • 从业者应具备内镜或鼻镜检查专长、全面的病理学知识以及接受过经验丰富专业人员的培训。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sclerotherapy involves injecting a sclerosing agent into the nasal, oral mucosa, and cutaneous telangiectasias to reduce bleeding, demonstrating both safety and efficacy as a treatment. Despite its proven benefits, few physicians currently offer this therapy to patients with hereditary hemorrhagic telangiectasia (HHT). OBJECTIVE: To promote the safe use of sclerotherapy among patients with HHT. DESIGN, SETTING, AND PARTICIPANTS: In this survey study, a modified Delphi protocol was used to achieve consensus on sclerotherapy among a panel of 6 experts. The Delphi consensus took place through online meetings and surveys sent via Google Forms. Six experts from Italy, Spain, and the US, each with more than 10 years of experience in the use of sclerotherapy for HHT-associated epistaxis and cutaneous telangiectasias, participated in the Delphi protocol. MAIN OUTCOMES AND MEASURES: This approach included 3 rounds of ratings interspersed with an in-person discussion led by an experienced moderator to resolve disagreements. Experts in using specific sclerotherapy agents (sodium tetradecyl sulfate and polidocanol), both in liquid or foam form, participated in surveys. Consensus was defined as agreement among 4 of 6 panelists. After discussions and clarifications, 3 survey rounds were conducted, resulting in consensus on all 30 statements across 7 domains. RESULTS: The consensus among 6 experts indicates that stable patients with HHT are eligible for sclerotherapy, with individualized precautions based on medical history and comorbidities. In-office sclerotherapy provides several advantages, including quick access, high patient satisfaction, and the elimination of general anesthesia risks, despite the occasional occurrence of vasovagal events and moderate bleeding. According to the 2015 European Society of Cardiology guideline, antibiotic prophylaxis is recommended for patient preparation, while fasting is generally not necessary. Specific precautions for preventing complications such as septal perforation and amaurosis were identified. Adverse effects are usually mild to moderate, with severe bleeding being rare. Practitioners should have expertise in endoscopy or rhinoscopy, thorough pathology knowledge, and training from experienced professionals. CONCLUSIONS AND RELEVANCE: In this survey study, the consensus of 6 experts produced 30 statements guiding patient care and safe procedure implementation. While not formal treatment guidelines, these statements offer valuable insights for clinicians seeking to adopt or align with expert recommendations. Further validation and research are encouraged to ensure these consensus statements improve patient care and outcomes.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Farneti P, Marcos-Salazar S, Crocione C, et al. Consensus on Sclerotherapy for Patients With Hereditary Hemorrhagic Telangiectasia-Related Epistaxis. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40773189. doi:10.1001/jamaoto.2025.2296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。